Commission Implementing Regulation (EU) 2025/901 of 19 May 2025 establishing a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species shall be six months and repealing Regulation (EC) No 1950/2006

The Commission Implementing Regulation (EU) 2024/2563 amends Implementing Regulation (EU) 2022/1646 regarding national risk-based control plans and surveillance plans, submission deadlines, and data transmission to EFSA. This Regulation aims to clarify reporting requirements and minimum sampling frequencies for certain substances, ensuring consistency with existing regulations and promoting efficient implementation of official controls in the EU. Main Purpose: The regulation aims to amend Implementing Regulation (EU) 2022/1646 to clarify reporting requirements and ensure consistency. Impact on Industry: This amendment ensures that Member States comply with Union legislation regarding the use of pharmacologically active substances, promoting a harmonized approach to official controls. Compliance Considerations: Member States must submit their national risk-based control plans and surveillance plan by specified deadlines, and transmit data to EFSA, while adhering to minimum sampling frequencies for certain substances.